Structural Determinants of HERG Channel Block by Clofilium and Ibutilide
Authors:
- Marcel J. de GrootMGMarcel J. de Groot
- Ray HelliwellRHRay Helliwell
- Derek LeishmanDLDerek Leishman
- Martin Tristani-FirouziMTMartin Tristani-Firouzi
- Michael C. SanguinettiMSMichael C. Sanguinetti
- John MitchesonJMJohn Mitcheson
- 1 August 2004
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 66 (2) , 240-249
Abstract
Block of human ether-a-go-go related gene (HERG) K+ channels by a variety of medications has been linked to acquired long QT syndrome, a disorder of cardiac repolarization that predisposes to lethal arrhythmias. The drug-binding site is composed of residues that face into the central cavity of the channel. Two aromatic residues located on the S6 domain (Tyr652 and Phe656) are particularly important structural determinants of drug block. The role of pore helix residues (Thr623, Ser624, Val625) is less clear. In this study, we compared the pharmacological properties of two structurally related compounds, ibutilide and clofilium. Both compounds are charged amines with a single phenyl ring. Clofilium, a chlorobenzene derivative, is a potent blocker of HERG channels, but has a remarkably slower time course for recovery from block than ibutilide, a methanesulfonanilide. The difference in the rate of recovery from block can be explained simply by variation in drug trapping. There is little recovery from clofilium block with D540K HERG channels that permit untrapping at hyperpolarized potentials. Alanine-scanning mutagenesis of the S6 domain and a portion of the pore helix revealed that the binding site residues were the same for both compounds. However, S624A, located at the base of the pore helix, was the only HERG mutation that enabled rapid recovery from clofilium block. In summary, the pore helix residues are important components of the HERG drug binding site, and may be particularly important for drugs with polar substituents, such as a halogen (e.g., clofilium) or a methanesulfonamide (e.g., ibutilide).Keywords
This publication has 31 references indexed in Scilit:
- The impact of drug-induced QT interval prolongation on drug discovery and developmentNature Reviews Drug Discovery, 2003
- X-ray structure of a voltage-dependent K+ channelNature, 2003
- Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241British Journal of Pharmacology, 2003
- Toward a Pharmacophore for Drugs Inducing the Long QT Syndrome: Insights from a CoMFA Study of HERG K+ Channel BlockersJournal of Medicinal Chemistry, 2002
- Blocker protection in the pore of a voltage-gated K+ channel and its structural implicationsNature, 2000
- QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug developmentPharmaceutical Science & Technology Today, 1999
- The Structure of the Potassium Channel: Molecular Basis of K + Conduction and SelectivityScience, 1998
- Cation-π Interactions in Chemistry and Biology: A New View of Benzene, Phe, Tyr, and TrpScience, 1996
- Use-dependent block and use-dependent unblock of the delayed rectifier K+ current by almokalant in rabbit ventricular myocytes.Circulation Research, 1993
- Induced Inactivation of the Potassium Permeability of Squid Axon MembranesNature, 1968